TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00824993
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
Study: NCT03890042
Drug: Gestodene-Ethinyl Estradiol
Normalized name: gestodene-ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynera tablet once daily
Study: NCT01651806
Drug: Males Weighted Dose TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weighted dose--20mg/kg of the drug will be given
Study: NCT00650806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One matching placebo capsule orally once daily for 12 weeks.
Study: NCT04765228
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin 50mg/m2 intravenous infusion on the first day + Anlotinib 12mg/d orally, medication on days 8-21, one cycle every 21 days, 2\~4 cycles
Study: NCT02834793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo in Randomization phase.
Study: NCT01523977
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m2 IV on days 4 and 5
Study: NCT04045405
Drug: CDR132L
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration
Study: NCT03835949
Drug: TJ004309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody to CD73
Study: NCT01043913
Drug: Guarana extract
Normalized name: guarana extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guarana extract 50mg q12 hours for 21 days
Study: NCT02549924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, 500 mg 3 times daily with the first bite of each meal
Study: NCT01876004
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/m2, IM (intramuscularly), single dose
Study: NCT01876004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed Placebo IM (intramuscularly), single dose
Study: NCT00838084
Drug: LY2811376
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT00838084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT01034748
Drug: [14C]PF00299804
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 45 mg oral dose of radiolabelled PF-00299804
Study: NCT01159652
Drug: bedtime placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01159652
Drug: middle of the night placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00381134
Drug: spironolactone 25 mg orally once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00381134
Drug: placebo once orally once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02925650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solid dosage form capsule
Study: NCT00314262
Drug: Erlotinib & Celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months.
Study: NCT04498260
Drug: Oral steroid - predonisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: (predonisolone)
Study: NCT04568161
Drug: Anthracycline & Cyclophosphamide treatment scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.
Study: NCT00016406
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00823680
Drug: RO5027838
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg po qd for 4 weeks
Study: NCT00823680
Drug: RO5093151
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg po bid for 4 weeks
Study: NCT03755960
Drug: routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
Study: NCT01363349
Drug: CYP-1020
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
Study: NCT01958489
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02198820
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia with proposal, rocuronium and sufentanil
Study: NCT00741026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
Study: NCT01902992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01702493
Drug: Cap SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
Study: NCT01702493
Drug: Tab SRT2104 slow release
Approvals — FDA: no, EMA: no, PMDA: no
Description: New 250 mg SRT2104 mesylate salt slow release tablet
Study: NCT01702493
Drug: Tab SRT2104 intermediate release
Normalized name: PREVOTELLA INTERMEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: New 250 mg SRT2104 mesylate salt intermediate release tablet
Study: NCT01702493
Drug: Selected formulations of SRT2104 from Part 1
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
Study: NCT01702493
Drug: Selected formulations of SRT2104 from Part 1 single alternative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
Study: NCT03099265
Drug: neoadjuvant mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
Study: NCT01717599
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
Study: NCT01717599
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
Study: NCT01433289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01002417
Drug: MCS-2 15 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
Study: NCT01002417
Drug: MCS-2 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
Study: NCT01002417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two matching placebo soft-gel capsules, oral daily for 12 weeks.
Study: NCT00324259
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01534897
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
Study: NCT01462253
Drug: Clofarabine, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
Study: NCT03613961
Drug: Anesthetics
Normalized name: ANESTHETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ANS plays an important role in the regulation of hemodynamics during anesthesia. Manually blous of propofol during induction anesthesia is reported to reduce both sympathetic and parasympathetic tone; however, it is not clear whether the changes in heart rate variability are associated with propofol concentration. We will observe the relationship of anesthetics and HRV dynamics.
Study: NCT01383343
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01383343
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00226759
Drug: OMS103HP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
Study: NCT00226759
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
Study: NCT00079027
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00117494
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00117494
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00220129
Drug: Epirubicin, Cisplatin, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00452361
Drug: Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maintenance dose of:~1. MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~2. AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~1. continued for the entire 104-week period of randomized therapy~2. subsequently discontinued~3. restarted after discontinuation
Study: NCT00512980
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00776919
Drug: clindamycin / benzoyl peroxide gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day application to the face
Study: NCT00776919
Drug: clindamycin gel
Normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day application to the face
Study: NCT00776919
Drug: vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day application to the face
Study: NCT02371941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT02129088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
Study: NCT00004908
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02672293
Drug: Phoslax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
Study: NCT00665808
Drug: isophane human insulin
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany
Study: NCT00862641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT02176252
Drug: AZD1722
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02176252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03091348
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate injection
Study: NCT00687141
Drug: AZD0328
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
Study: NCT00687141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
Study: NCT02753439
Drug: Geistlich Bio Oss
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction of Impacted 3rd Molars,
Study: NCT01233232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose bid
Study: NCT01233232
Drug: AZD5069 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose bid
Study: NCT01233232
Drug: AZD5069 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose bid
Study: NCT02230917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02141737
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
Study: NCT02141737
Drug: Fentanyl Citrate Injection
Normalized name: Fentanyl Citrate Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
Study: NCT02867384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01395524
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg oral tablet once daily
Study: NCT01395524
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral tablet once daily
Study: NCT01395524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet intake once daily
Study: NCT01217307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily during 4 months
Study: NCT02479308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be matched to Moxifloxacin or ALKS 5461
Study: NCT01186172
Drug: Ethanol-lock therapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
Study: NCT01186172
Drug: Antibiotic-lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
Study: NCT01502267
Drug: High dose IVIG and B cell depleting agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. IVIG(2g/kg two times on day 1, 30)~2. Rituximab(375mg/m2 on day 3)~3. Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)
Study: NCT01141569
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01794143
Drug: Sulfonylurea (glimepiride)
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used in accordance with labeling and/or usual practice.
Study: NCT04001530
Drug: Half Normal Saline 0.45% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization to half normal saline
Study: NCT04001530
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization to normal saline
Study: NCT01277770
Drug: Steroid-Free Maintenance Immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 year follow-up of steroid-free maintenance immunosuppression
Study: NCT01310803
Drug: VALSTAR - Maintenance Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
Study: NCT02284880
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF - Marketed formulation
Study: NCT02817425
Drug: SOX Sequential S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.
Study: NCT02817425
Drug: TEGAFOX Sequential S-1.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 \~14 (S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
Study: NCT02604160
Drug: LY3113593
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by slow intravenous (IV) infusion.
Study: NCT02604160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by slow intravenous (IV) infusion.
Study: NCT01511120
Drug: Tetraspan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00492635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
Study: NCT03771170
Drug: Rheosorbilact®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
Study: NCT03771170
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Study: NCT00662675
Drug: Pancrease MT 10.5, or MT 21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
Study: NCT00662675
Drug: Placebo for Pancrease MT 10.5 or MT 21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules with Pancrease MT excipients without the active enzymes
Study: NCT00552188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dosing, 1 time daily for 24 weeks
Study: NCT02160899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline as Placebo, subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
Study: NCT03137264
Drug: Other
Normalized name: others
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
Study: NCT01168219
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00490529
Drug: Standard induction chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific, regular medical care treatment as determined by treating oncologist
Study: NCT00490529
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular medical care treatment to mobilize peripheral blood progenitor cell (PBPC)
Study: NCT04657666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oromucosal spray
Study: NCT02468167
Drug: Lauromacrogol
Normalized name: Lauromacrogol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03300804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo herb formulation
Study: NCT00087763
Drug: Macugen ™ (pegaptanib sodium injection)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00229424
Drug: Lafutidine
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of lafutidine by 20mg/day along with famotidine placebo
Study: NCT01696604
Drug: GSK2849466
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
Study: NCT01696604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules will be available.
Study: NCT00367783
Drug: CP-741,952
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04270760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 5
Study: NCT04090801
Drug: Topical minoxidil 5% in 90% ethanol and 5% propylene glycol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04090801
Drug: Topical minoxidil 5% in pure ethanol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
Study: NCT01223742
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice per day
Study: NCT00591318
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
Study: NCT00647270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringe. See arm for more detail
Study: NCT02523144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored placebo syrup
Study: NCT02152280
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
Study: NCT02152280
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
Study: NCT00131053
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00131053
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no